Welcome to our dedicated page for Oaktree Acquisition III Life Sciences news (Ticker: OACCU), a resource for investors and traders seeking the latest updates and insights on Oaktree Acquisition III Life Sciences stock.
Oaktree Acquisition Corp. III Life Sciences (OACCU) provides investors with centralized access to official corporate communications and strategic developments for this life sciences-focused SPAC. This resource aggregates all verified news releases, merger disclosures, and regulatory filings related to OACCU's pursuit of acquisition targets in biotechnology and medical innovation sectors.
Market participants can monitor critical updates including potential merger announcements, leadership changes, and capital allocation decisions. The curated collection serves as a reliable reference for SPAC performance analysis, offering timestamped records of material events affecting shareholder value.
Key content includes prospectus supplements, SEC Form 8-K filings, and partnership disclosures. Users benefit from chronological organization that maintains context for strategic decisions while preserving regulatory compliance in financial reporting.
Bookmark this page for streamlined tracking of OACCU's progress in identifying and evaluating life sciences acquisition targets. Check regularly for updates on this blank check company's navigation of complex merger negotiations and capital deployment strategies.
Oaktree Acquisition Corp. III Life Sciences announced that starting December 16, 2024, holders of units from its initial public offering can separately trade Class A ordinary shares and warrants. Units will continue trading on Nasdaq as 'OACCU', while separated Class A shares and warrants will trade under 'OACC' and 'OACCW' respectively.
To separate units, holders must contact Continental Stock Transfer & Trust Company. Only whole warrants will trade, with no fractional warrants issued. The initial offering was underwritten by Jefferies , Citigroup Global Markets Inc., and UBS Investment Bank as joint book-running managers. The SEC declared the registration statement effective on October 23, 2024.
Oaktree Acquisition Corp. III Life Sciences has announced the pricing of its initial public offering (IPO) of 17,500,000 units at $10.00 per unit, totaling $175 million. The units will trade on Nasdaq under OACCU starting October 24, 2024. Each unit includes one Class A ordinary share and one-fifth of a redeemable warrant. Whole warrants allow holders to purchase shares at $11.50 each. The company granted underwriters a 45-day option to purchase up to 2,625,000 additional units. Jefferies, Citigroup, and UBS Securities are serving as joint book-running managers.
FAQ
What is the current stock price of Oaktree Acquisition III Life Sciences (OACCU)?
